 | • レポートコード：B-MOR-08177 • 出版社/出版日：Mordor Intelligence / 2018年6月20日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、経腸栄養製剤の世界市場について調べ、経腸栄養製剤の世界規模、市場動向、市場環境、製品別（ポリマー、モノマー、疾患特異的製剤）分析、用途別（腫瘍、神経、救命医療、糖尿病、消化器）分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・経腸栄養製剤の世界市場インサイト ・経腸栄養製剤の世界市場環境 ・経腸栄養製剤の世界市場動向 ・経腸栄養製剤の世界市場規模 ・経腸栄養製剤の世界市場規模：製品別（ポリマー、モノマー、疾患特異的製剤） ・経腸栄養製剤の世界市場規模：用途別（腫瘍、神経、救命医療、糖尿病、消化器） ・経腸栄養製剤の世界市場規模：エンドユーザー別 ・経腸栄養製剤の世界市場：地域別市場規模・分析 ・経腸栄養製剤の北米市場規模・予測 ・経腸栄養製剤のアメリカ市場規模・予測 ・経腸栄養製剤のヨーロッパ市場規模・予測 ・経腸栄養製剤のアジア市場規模・予測 ・経腸栄養製剤の日本市場規模・予測 ・経腸栄養製剤の中国市場規模・予測 ・経腸栄養製剤のインド市場規模・予測 ・経腸栄養製剤の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global enteral feeding formulas market is expected to register a growth rate of CAGR of 7.5% during the forecast period, 2018-2023. The key factors propelling the growth of the market are the rise in geriatric population around the world, rising prevalence of preterm births and increasing number of chronic diseases. Most of the patients face severe complications in oral food intake owing to the head and neck cancer. According to the estimates of National Cancer Institute in the United States, 1,735,350 new cases are expected to be diagnosed in 2018 and 609,640 people are likely die from the disease. North America is expected to dominate the market owing to the high healthcare expenditure, a huge prevalence of chronic diseases, and better reimbursement policies.
Increasing Prevalence of Chronic Diseases
The high prevalence rate of chronic disorders such as cancer, cardiovascular diseases, diabetes, and (Coronary Obstructive Pulmonary Disorders) COPD are expected to propel the growth of the market. Cardiovascular diseases impose a huge burden in terms of mortality, morbidity, and healthcare costs. According to the estimates of CVD statistics reported by World Health Organization (WHO), cardiovascular diseases accounted for 31% of overall deaths in 2015. In addition, the data states that globally nearly 1 in 6 deaths are caused by cancer. These chronic diseases require longer hospital stay and recovery time, thus patients face problem in swallowing food. External nutrition’s are given to the patient through the tube. Thus the increase in cases of chronic diseases, such as cancer and cardiovascular diseases are expected to drive the growth of the market over the forecasted period.
Other factors driving this market are the growing geriatric population around the world, rising prevalence of preterm births, and increasing prevalence of chronic diseases.
Complications Associated With Enteral Nutrition
The complications associated with enteral nutrition comprise gastrointestinal, mechanical, metabolic complications. In gastrointestinal complications, approximately 20% of patients experience nausea and vomiting while feeding through the tube. The mechanical complications comprise of aspiration, tube malposition, and tube clogging. The metabolic complications can lead to hyponatremia, dehydration, hyperglycemia, hypokalemia, and hyperkalemia. The aforementioned complications are expected to hamper the growth of this market over the forecasted period.
Other factors that will act as restraints on the market include patient safety risks and occurrence of feeding or medication errors.
North America to Dominate the Market
North America is expected to dominate the enteral feeding formulas market owing to factors such as rapid aging population, surging prevalence of preterm birth, and rise in the number of chronic disease patients. In the United States it is projected that the number of people above the age of 65 years will be more than double till 2060. The rise in geriatric population will increase the cases of chronic diseases such as cancer CVD, and diabetes which will further lead to increase in a hospital stay of the patient. In addition, as per the data published by WHO 15 million babies are born preterm and this number is rising. Hence, all of the above mentioned factors are expected to drive the market growth.
Key Developments in the Market
• March 2017 – Trovita Health Science, an emerging life science company specializing in medical nutrition, announces U.S. Food and Drug Administration marketing authorization of the new SAFE-T FEED device for administering tube feeding formulas.
Major Players – ABBOTT, NESTLE S.A., DANONE NUTRICIA, FRESENIUS KABI AG, B. BRAUN MELSUNGEN AG, MEAD JOHNSON & COMPANY, LLC, TROVITA HEALTH SCIENCE, GLOBAL HEALTH PRODUCT INC., MEIJI HOLDINGS CO. LTD, and VICTUS amongst others.
Reasons to Purchase this Report
• Current and future global enteral feeding formulas market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• Three months analyst support, along with the Market Estimate sheet (in excel)
Customization of the report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Pipeline Analysis
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Consumers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitute Product and Services
5.3.5 Competitive Rivalry within the Industry
5.4 Regulatory Scenario
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Growing Geriatric Population Across the Globe
6.1.2 Rising Prevalence of Preterm Births
6.1.3 Increasing Prevalence of Chronic Diseases
6.2 Market Restraints
6.2.1 Complications associated with enteral nutrition
6.2.2 Patient Safety Risks and Occurrence of Feeding or Medication Errors
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Product
7.1.1 Polymeric
7.1.2 Monomeric
7.1.3 Disease-Specific Formulas
7.2 By Application
7.2.1 Oncology
7.2.2 Neurology
7.2.3 Critical Care
7.2.4 Diabetes
7.2.5 Gastroenterology
7.2.6 Others
7.3 By End User
7.3.1 Hospitals
7.3.2 Home Care Agencies and Hospices
7.3.3 Nursing Homes
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest Of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott
9.2 Nestle S.A.
9.3 Danone Nutricia
9.4 Fresenius Kabi AG
9.5 B. Braun Melsungen AG
9.6 Mead Johnson & Company, LLC.
9.7 Trovita Health Science
9.8 Global health Product, Inc.
9.9 Meiji Holdings Co., Ltd.,
9.10 VICTUS
*List Not Exhaustive
10. Future of the Market